Kodiak Sciences Announces Completion of Enrollment in the Company’s Phase 1 Safety and Tolerability Study in Patients with Retinal Disease
Palo Alto, CA, August 31, 2018 – Kodiak Sciences Inc., a clinical stage biopharmaceutical company specializing in novel therapeutics to treat high prevalence ophthalmic diseases, today announced that enrollment of patients in the company’s phase 1 safety and tolerability study has been completed. First patient in was dosed on July 12, 2018 and last patient in was dosed on August 13, 2018.
KSI-301 is the first of Kodiak’s pipeline of Antibody Biopolymer Conjugate, or ABC, products to reach the clinic. KSI-301 is an investigational agent for the treatment of patients with retinal vascular diseases including neovascular age related macular degeneration (wet AMD) and diabetic eye disease. KSI-301 is an intravitreally administered anti-VEGF biological agent with an extended durability profile.
The phase 1 trial is being conducted in the USA as an open label, single ascending dose study enrolling patients with diabetic macular edema. The primary objectives of the phase 1 study are to evaluate ocular and systemic safety and to establish a maximum tolerated dose of KSI-301. To date, the study drug has been safe and well tolerated in all subjects with no signs of ocular inflammation or drug related adverse events at any dose. Dose escalation culminated in a maximal tested dose of 5.0mg. The first patient was dosed by Dr. Pravin Dugel of Retinal Consultants of Arizona. Other patients were dosed by participating investigators Dr. Sunil Patel, Dr. David Boyer, and Dr. Richard McDonald.
The phase 1 study is a point of departure for a series of proposed phase 1b and phase 2 studies for KSI-301 in wet AMD and diabetic retinopathy.
About Kodiak Sciences Inc.
Kodiak Sciences is a clinical stage company developing innovative therapeutics to treat high prevalence ophthalmic diseases. We aspire to global leadership in ophthalmology through internal focus and by aggregating top talent, technologies, discoveries and ideas. Our Antibody Biopolymer Conjugate, or ABC™, platform merges the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak’s discovery engine. In addition to its lead product candidate, KSI-301, a potential best in class molecule for age-related macular degeneration and diabetic retinopathy, Kodiak has leveraged its ABC platform to build a pipeline of product candidates in various stages of development including KSI-501, a dual inhibitor ABC for the treatment of retinal disease. Kodiak is based in Palo Alto, CA.
Kodiak Contact:
John Borgeson
Senior Vice President and Chief Financial Officer
Tel (650) 281-0850
media@kodiak.com